Document Detail

Amiodarone in the new AHA guidelines for ventricular tachyarrhythmias.
MedLine Citation:
PMID:  11675855     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To delineate amiodarone's role in the new American Heart Association guidelines for ventricular tachyarrhythmias, review the literature that supports the use of amiodarone in ventricular tachyarrhythmias, describe the pharmaceutical properties of amiodarone and elucidate their clinical implications, and discuss the dosing, preparation, and administration of amiodarone.
DATA SOURCES: A search of MEDLINE (1966-October 2000) database and EMBASE Drugs and Pharmacology database (1980-October 2000) was performed. References from published articles and tertiary references were used to gather additional data.
DATA EXTRACTION: All articles were screened, and pertinent studies were identified and evaluated.
DATA SYNTHESIS: Recent trials have demonstrated amiodarone's usefulness in the setting of ventricular tachyarrhythmias. Based on these investigations and contrary to past guidelines, amiodarone is included in the 2000 advanced cardiovascular life support guidelines as a possible agent for hemodynamically stable monomorphic ventricular tachycardia (VT), non-QT prolonged polymorphic VT, and ventricular fibrillation (VF)/pulseless VT. Although not specifically evaluated in the setting of hemodynamically stable monomorphic VT and non-QT prolonged polymorphic VT, investigations by the intravenous Amiodarone Multicenter Trial Group and other clinical trials make amiodarone an acceptable choice for these arrythmia categories. The results of the ARREST (Resuscitation of Refractory Sustained Ventricular Tachyarrhythmias) trial prove amiodarone to be the antiarrhythmic of choice for VF/pulseless VT.
CONCLUSIONS: Amiodarone is classified as a IIb therapeutic intervention for all three arrhythmia categories, which makes it an acceptable, safe, and useful agent with fair to good evidence to support its use. In addition, amiodarone requires careful preparation and delivery to achieve safe and effective outcomes.
M F Caron; J Kluger; C M White
Related Documents :
19653175 - Predictors of ventricular tachycardia induction in syncopal patients with mild to moder...
16443535 - Characterization of the infarct substrate and ventricular tachycardia circuits with non...
10534025 - Pharmacologic treatment of cardiac arrest.
1638705 - Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as del...
14669085 - Pericardiectomy to treat constrictive pericarditis in a patient with hyperbilirubinemia...
15319365 - Epigallocatechin-3-gallate inhibits stat-1 activation and protects cardiac myocytes fro...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  35     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-24     Completed Date:  2002-03-05     Revised Date:  2014-07-28    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1248-54     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
American Heart Association
Amiodarone / administration & dosage,  therapeutic use*
Anti-Arrhythmia Agents / administration & dosage,  therapeutic use*
Cardiopulmonary Resuscitation / methods*
Infusions, Intravenous
Life Support Care
Practice Guidelines as Topic*
Randomized Controlled Trials as Topic
Tachycardia, Ventricular / drug therapy*
United States
Reg. No./Substance:
0/Anti-Arrhythmia Agents; N3RQ532IUT/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiplatelet agents for secondary prevention of ischemic stroke.
Next Document:  Antimicrobial-coated/bonded and -impregnated intravascular catheters.